Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FORTIFY
- Sponsors AbbVie; AbbVie Germany
- 19 Feb 2024 According to AbbVie Media Release, data from the study will be presented at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.
- 17 Oct 2023 Results of a post-hoc analysis assessing EIM resolution in patients with moderate to severe Crohn's disease (CD) who received risankizuma using pooled data from ADVANCE, MOTIVATE and FORTIFY studies presented at the 31st United European Gastroenterology Week
- 17 Oct 2023 Results assessing to conduct a placebo anchored matching-adjusted indirect comparison of endoscopic outcomes between upadacitinib and ustekinumab among patients with moderately to severely active CD from phase 3 UPA trials (NCT03105128, 03104413, 03105102) and UST endoscopy sub-studies (NCT01369329, 01369342, 01369355) from the phase 3 UNITI/IM-UNITI program, presented at the 31st United European Gastroenterology Week.